Article
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.
Leukemia & lymphoma - 1 Feb 2010
Carella Angelo M, Garuti Anna, Cirmena Gabriella, Catania Gioacchino, Rocco Ilaria, Palermo Claudia, Pica Gianmatteo, Pierri Ivana, Miglino Maurizio, Ballestrero Alberto, Gobbi Marco, Patrone Franco
Abstract excerpt
Acquired resistance to imatinib in the advanced phase of chronic myeloid leukemia (CML) has been associated with mutations in the kinase domain (KD) of BCR-ABL. On the contrary, the prognostic implication of KD mutations in early chronic phase (CP) patients at diagnosis before imatinib-based therapy has not yet been established. We have reviewed the status of mutations in 43 patients with early CP-CML on the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.